Evaluating the safety of β-interferons in MS

Hilda J.I. De Jong, Elaine Kingwell, Afsaneh Shirani, Jan Willem Cohen Tervaert, Raymond Hupperts, Yinshan Zhao, Feng Zhu, Charity Evans, Mia L. Van Der Kop, Anthony Traboulsee, Paul Gustafson, John Petkau, Ruth Ann Marrie, Helen Tremlett

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Objective: To examine the association between interferon-β (IFN-β) and potential adverse events using population-based health administrative data in British Columbia, Canada. Methods: Patients with relapsing-remitting multiple sclerosis (RRMS) who were registered at a British Columbia Multiple Sclerosis Clinic (1995-2004) were eligible for inclusion and were followed up until death, absence from British Columbia, exposure to a non-IFN-β disease-modifying drug, or December 31, 2008. Incidence rates were estimated for each potential adverse event (selected a priori and defined with ICD-9/10 diagnosis codes from physician and hospital claims). A nested case-control study was conducted to assess the odds of previous IFN-β exposure for each potential adverse event with at least 30 cases. Cases were matched by age (±5 years), sex, and year of cohort entry, with up to 20 randomly selected (by incidence density sampling) controls. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated with conditional logistic regression adjusted for age at cohort entry. Results: Of the 2,485 eligible patients, 77.9% were women, and 1,031 were treated with IFN-β during follow-up. From the incidence analyses, 27 of the 47 potential adverse events had at least 30 cases. Patients with incident stroke (OR adj 1.83, 95% CI 1.16-2.89), migraine (OR adj 1.55, 95% CI 1.18-2.04), depression (OR adj 1.33, 95% CI 1.13-1.56), and hematologic abnormalities (OR adj 1.32, 95% CI 1.01-1.72) were more likely to have previous exposure to IFN-β than controls. Conclusions: Among patients with RRMS, IFN-β was associated with a 1.8- and 1.6-fold increase in the risk of stroke and migraine and 1.3-fold increases in depression and hematologic abnormalities.

Original languageEnglish (US)
Pages (from-to)2310-2320
Number of pages11
JournalNeurology
Volume88
Issue number24
DOIs
StatePublished - Jun 13 2017

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Evaluating the safety of β-interferons in MS'. Together they form a unique fingerprint.

  • Cite this

    De Jong, H. J. I., Kingwell, E., Shirani, A., Tervaert, J. W. C., Hupperts, R., Zhao, Y., Zhu, F., Evans, C., Van Der Kop, M. L., Traboulsee, A., Gustafson, P., Petkau, J., Marrie, R. A., & Tremlett, H. (2017). Evaluating the safety of β-interferons in MS. Neurology, 88(24), 2310-2320. https://doi.org/10.1212/WNL.0000000000004037